Head-to-head · Cost-Efficiency Index
Ivy Rx vs Revel Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Ivy Rx
Cost-first shoppers who want the lowest published entry price on a semaglutide microdose, for shoppers comfortable with unresolved pricing terms.
Visit Ivy RxRevel Health
Cost-first shoppers who want gLP-1 weight loss bundled with longevity add-ons, if the first-month promo price isn't mistaken for the ongoing rate.
Visit Revel HealthThe verdict
Ivy Rx and Revel Health tie on the Cost-Efficiency Index at 69/100, so neither wins outright on the numbers. For most shoppers we'd start with Ivy Rx (ranked #102, a hair above #107) — Cost-first shoppers who want the lowest published entry price on a semaglutide microdose, for shoppers comfortable with unresolved pricing terms. But Revel Health is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Ivy Rx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Ivy Rx | Revel Health |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 69/100 |
| Semaglutide / mo | $97/mo (microdose tier, promotional rate, compounded) | $199/mo (starting dose, promotional rate, compounded) |
| Tirzepatide / mo | $199/mo (brand Mounjaro, compounded) | $249/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $1,164 | $2,388 |
| Tirzepatide / yr (modeled) | $2,388 | $2,988 |
| Coverage | All 50 states | 45 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #102 | #107 |
Ivy Rx
69/100Where the value is
- Genuinely low entry price on the semaglutide microdose tier ($77/mo)
- HSA/FSA eligible with itemized receipts for reimbursement
- Legal entity is named (Ivy RX PLLC), which many competitors in this batch do not disclose
The tradeoffs
- The standard semaglutide price is shown as a struck-through discount ('$197 $97') with no label clarifying whether $97 is a standing rate or a temporary promo
- The advertised $199/mo tirzepatide rate requires a 12-month upfront lump-sum payment, not month-to-month billing, and a separate unexplained $1,399 vial price appears on the same page
Revel Health
69/100Where the value is
- All-in pricing confirmed on-site — consultation, medication, supplies, and shipping in one number, no add-on fees disclosed
- LegitScript verification seal is live and checkable for myrevelhealth.com
- Explicit, specific 45-state coverage list published rather than a vague claim
The tradeoffs
- The prominently displayed $99/$149 figures are first-month-only promotional prices — the standing rate from month two on is $199/$249, and the page's side-by-side display makes the promo easy to mistake for the ongoing price
- Not available in AK, AR, NC, NJ, or MS
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.